WINDSOR, Ontario - GeorgiaChron -- On June 21, 2019, CEN Biotech, Inc. (the "Company") entered into a Merger Agreement (the "Merger Agreement") with Caduceus Software Systems Corp., a Wyoming corporation ("CSOC") and Caduceus Merger Sub, Inc., a Wyoming corporation and a wholly owned subsidiary of CSOC (the "Merger Sub"). Pursuant to the Merger Agreement, the Company, the Merger Sub and CSOC agreed to effect a merger transaction, pursuant to which the Company would merge with and into the Merger Sub, with the Company surviving and being a wholly owned subsidiary of CSOC (the "Merger").
The Merger Agreement was subsequently amended to extend the termination date under the Merger Agreement (i.e., the date following which a party to the Merger Agreement may terminate the Merger Agreement if the Merger and the transactions in the Merger Agreement have not closed as of that time) from August 30, 2019 to December 31, 2019 and also to remove the prohibition in the Merger Agreement from the Company soliciting or initiating discussions with third parties regarding other acquisition proposals.
Pursuant to the Merger Agreement, the Company had the unilateral right to terminate the Merger Agreement in the event that the Company's due diligence review of CSOC and Merger Sub were unsatisfactory to the Company in its sole discretion. Following a careful due diligence review of CEN and Merger Sub, the Board of the Company decided that such due diligence review was unsatisfactory, and therefore the Company terminated the Merger Agreement as of November 20, 2019.
More on Georgia Chron
About CEN Biotech, Inc.
CEN Biotech, Inc. is a global holding company—dedicated to identifying and developing alternative approaches to business opportunities in diversified, yet related industries. With core operations focused on North America, Eastern Europe and China, CEN Biotech is continually looking to develop its dynamic and unique businesses, by seeking to leverage exclusive relationships with governments and private enterprises, around the world. In addition to CEN's focus on improving the health and wellness of people, CEN also has proprietary technologies, which it believes has widespread commercial application in the Industrial, Automotive, and Agriculture sectors.
Forward-looking Statements
This press release contains "forward-looking" statements. In particular, the words "believe," "may," "could," "should," "expect," "anticipate," "estimate," "project," "propose," "plan," "intend," and similar conditional words and expressions are intended to identify forward-looking statements. Any statements made in this press release about an action, event or development, are forward-looking statements. These forward-looking statements are only predictions and are subject to certain risks, uncertainties and assumptions, many of which may be beyond control of CEN, that could cause actual results to differ from those in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. Although CEN believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Potential risks include such factors as the inability to enter into agreements with parties with whom we are in discussions, factors that cannot be predicted with certainty, as well as additional risks and uncertainties that are identified and described in CEN's reports filed with the Securities and Exchange Commission (the "SEC"). Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. Actual results may differ materially from the forward-looking statements in this press release. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. CEN does not undertake, and it specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events or circumstances after the date of such statement. You can also obtain additional information regarding CEN in CEN's filings with the SEC.
More on Georgia Chron
Media Inquiries can be sent to:
Brian Payne, Vice President
CEN Biotech Inc.
(519) 419-4958, Extension 1506
brian@cenbiotechinc.com
The Merger Agreement was subsequently amended to extend the termination date under the Merger Agreement (i.e., the date following which a party to the Merger Agreement may terminate the Merger Agreement if the Merger and the transactions in the Merger Agreement have not closed as of that time) from August 30, 2019 to December 31, 2019 and also to remove the prohibition in the Merger Agreement from the Company soliciting or initiating discussions with third parties regarding other acquisition proposals.
Pursuant to the Merger Agreement, the Company had the unilateral right to terminate the Merger Agreement in the event that the Company's due diligence review of CSOC and Merger Sub were unsatisfactory to the Company in its sole discretion. Following a careful due diligence review of CEN and Merger Sub, the Board of the Company decided that such due diligence review was unsatisfactory, and therefore the Company terminated the Merger Agreement as of November 20, 2019.
More on Georgia Chron
- Invesco Advisers Announces Final Results of Tender Offers for Invesco Dynamic Credit Opportunities Fund, Invesco High Income Trust II and Invesco Senior Income Trust
- Macon: Government Office hours, Trash Collection schedule for Christmas & New Year's Day
- Macon: IT Department seeking feedback to help better provide information, services
- CEO Coaching International Congratulates Clients, Bryce Maddock and Jaspar Weir of TaskUs, on Winning the EY National Entrepreneur of the Year 2019
- North Highland Named Leader and Best in Class Provider for Corporate Services by ALM Intelligence
About CEN Biotech, Inc.
CEN Biotech, Inc. is a global holding company—dedicated to identifying and developing alternative approaches to business opportunities in diversified, yet related industries. With core operations focused on North America, Eastern Europe and China, CEN Biotech is continually looking to develop its dynamic and unique businesses, by seeking to leverage exclusive relationships with governments and private enterprises, around the world. In addition to CEN's focus on improving the health and wellness of people, CEN also has proprietary technologies, which it believes has widespread commercial application in the Industrial, Automotive, and Agriculture sectors.
Forward-looking Statements
This press release contains "forward-looking" statements. In particular, the words "believe," "may," "could," "should," "expect," "anticipate," "estimate," "project," "propose," "plan," "intend," and similar conditional words and expressions are intended to identify forward-looking statements. Any statements made in this press release about an action, event or development, are forward-looking statements. These forward-looking statements are only predictions and are subject to certain risks, uncertainties and assumptions, many of which may be beyond control of CEN, that could cause actual results to differ from those in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. Although CEN believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Potential risks include such factors as the inability to enter into agreements with parties with whom we are in discussions, factors that cannot be predicted with certainty, as well as additional risks and uncertainties that are identified and described in CEN's reports filed with the Securities and Exchange Commission (the "SEC"). Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. Actual results may differ materially from the forward-looking statements in this press release. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. CEN does not undertake, and it specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events or circumstances after the date of such statement. You can also obtain additional information regarding CEN in CEN's filings with the SEC.
More on Georgia Chron
- Macon-Bibb to celebrate new facilities, improvements at Henderson Stadium
- Donna Markussen Releases Her New Women's Health Book, "Take Command of Your Total Health"
- CANCrocodile - Contactless CAN Bus, SAE J1939, FMS, OBD-II, And SAE J1708 Reader
- Bootstrapped SaaS startup JustCall ranks 54th Fastest Growing Company on Deloitte's APAC Technology Fast 500
- Successful Pageant Queen Turned Author & Ex Dash Doll Opens Up About Her Painful Past
Media Inquiries can be sent to:
Brian Payne, Vice President
CEN Biotech Inc.
(519) 419-4958, Extension 1506
brian@cenbiotechinc.com
Source: CEN Biotech Inc.
Filed Under: Business
0 Comments
Latest on Georgia Chron
- Rapper Lil Cory Arrested On Disorderly Conduct
- Is "Trump and His Magic Wand" really worth 150 Million?
- Dr. Clyde Lettsome Serves on NCEES Computer Engineering Exam Writing Committee
- City of Atlanta to Open Warming Center Wednesday Ahead of Frigid Weather
- 626 acquires the leading injector service solution provider in the Healthcare Technology Management space
- Mayor Keisha Lance Bottoms Announces Most Significant Atlanta Fire Rescue Department Compensation Raises in 15 Years
- TMG, ranked No. 1 on Best Places to Work list for 2nd year in a row, moves into third party management
- Cosmo Nail Lounge Grand Opening at North Point Mall Introduces Atomy Brand Skin Care Line
- Skylar Lanier Joins Carriage Trade Public Relations® and Cecilia Russo Marketing as PR Coordinator
- Evolve IP Completes Flex Certification for WebEx Calling and Meetings Solutions
- Trans Actor Jesse Todd Tapped for Lead Role in Upcoming Film "Pink Moon"
- Zbones Discovers Additional Eardrums In Humans!
- New Podcast Highlights Local Events for Greater Savannah Area
- Aldo Dinelli, Houston's Top Celebrity Jeweler - Talks Diamonds
- Mayor Keisha Lance Bottoms to Make Announcement on Atlanta Fire Rescue Department
- Santia Deck Makes History; Signs Record Breaking Deal With Highly-Anticipated WFLA
- Dbvisit Announces Release of Dbvisit Standby Snapshot
- Vogtle Unit 3 shield building roof set
- Apollo Brands® Announces Exclusive Distribution Agreement Bringing Apollo Energy Gum® and Golf Gum® to The Nordic Countries
- Sandline Discovery Leverages NexLP's Cognitive AI to Deliver Leading Behavioral and Linguistic Intelligence